

Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA)

Minutes of the 65th Plenary meeting

11-12 June 2015, (EFSA)

(Agreed on 24 June 2015)

Participants

- **Panel Members:**

Carlo Agostoni, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Rosangela Marchelli, Ambroise Martin (Chair), Androniki Naska, Monika Neuhäuser-Berthold, Grazyna Nowicka, Alfonso Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen.

- **Hearing Experts¹:**

- Not Applicable

- **European Commission and/or Member States representatives:**

- Olga Goulaki² (DG SANTE)

- **EFSA:**

- Nutrition Unit: Valeriu Curtui, Reinhard Ackerl, Anja Bronstrup, Janusz Ciok, Lucia Fabiani, Wolfgang Gelbmann, Leng Heng and Emanuela Turla.

- **Others:**

- Jenny Reid (short-term visiting Scientist, Ministry for Primary Industry, New Zealand)

1. Welcome and apologies for absence

The Chair welcomed the participants.

Apologies were received from Roberto Berni Canani, Sébastien La Vieille, Yolanda Sanz and Martin Stern.

2. Adoption of the agenda

The agenda was adopted with changes in the order of discussion.

¹ As defined in Article 11 of the Decision of the Executive Director on Declarations of Interest: <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

² Present on 11 June.

3. Declarations of Interest of Scientific Panel Members

In accordance with EFSA's Policy on Independence and Scientific Decision-Making Processes³ and the Decision of the Executive Director on Declarations of Interest⁴, EFSA screened the Annual Declarations of Interest and the Specific Declarations of Interest filled in by the Panel Members invited for the present meeting. For further details on the outcome of the screening of the SDoI, please refer to Annex I.

No other conflicts of interests related to the issues discussed in this meeting were identified during the screening process or at the Oral Declaration of Interest at the beginning of this meeting.

4. Report on written procedures since 64th Plenary meeting

There were no written procedures to report to the Panel.

5. Scientific outputs submitted for discussion and/or possible adoption

Applications pursuant to Article 14/13.5 of Regulation (EC) No 1924/2006

- 5.1. *Cross Vetpharm Group – "Colief/lactase enzyme reduces the lactose load of the infant's feed and improves the consequences of lactose maldigestion in colicky infants unable to effectively digest all the lactose in their feed"*** (Art. 14, 0417_UK, EFSA-Q-2014-00404)

The discussion of this agenda item was postponed to the next NDA plenary meeting⁵.

- 5.2. *Han-Asiabiotech GmbH – "Symbiosal®" and "lowers the rising of blood pressure when used as a replacement of traditional table salt. The rising of blood pressure is a risk factor for hypertension"***⁶ (Art. 14, 0415_DE, EFSA-Q-2014-00366)

On 11 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text will be published in the EFSA Journal in the coming weeks via this link:
<http://www.efsa.europa.eu/en/efsajournal/pub/4147.htm>

Novel Foods

- 5.3. *Glycom A/S - Lacto-N-neotetraose*** (EFSA-Q-2014-00862)

On 11 June, the draft opinion was presented and discussed. The NDA Panel comments will be forwarded to the WG on Novel Foods for revising the draft opinion. A revised draft will be submitted to the next NDA plenary meeting⁵ for further discussion and possible adoption.

- 5.4. *Glycom A/S - 2'-O-Fucosyllactose*** (EFSA-Q-2015-00052)

On 11 June, the draft opinion was presented and discussed. The NDA Panel comments will be forwarded to the WG on Novel Foods for revising

³ <http://www.efsa.europa.eu/en/keydocs/docs/independencepolicy.pdf>

⁴ <http://www.efsa.europa.eu/en/keydocs/docs/independencerules2014.pdf>

the draft opinion. A revised draft will be submitted to the next NDA plenary meeting⁵ for further discussion and possible adoption.

5.5. Viasolde AB - UV light treated bread (EFSA-Q-2014-00836)

On 11 June, the draft opinion was discussed and adopted by the Panel subject to the incorporation of editorial changes. The full text will be published in the EFSA Journal in the coming weeks via this link: <http://www.efsa.europa.eu/en/efsajournal/pub/4148.htm>

Dietary Reference Values

5.6. Draft technical report on the outcome of the public consultation on the Draft Scientific Opinion on the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on Dietary Reference Values for phosphorus (EFSA-Q-2015-00098)

The discussion of this agenda item was postponed to the next NDA plenary meeting⁵.

5.7. Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Dietary Reference Values for phosphorus (EFSA-Q-2011-01220)

The discussion of this agenda item was postponed to the next NDA plenary meeting⁵.

5.8. Draft technical report on the outcome of the public consultation on the Draft Scientific Opinion on the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on Dietary Reference Values for vitamin E as α -tocopherol (EFSA-Q-2015-00099)

A technical report on the Outcome of a public consultation on a draft Opinion related to the dietary reference values for vitamin E as α -tocopherol, which summarises the comments received during the public consultation on this opinion (which was open from 9 March to 13 April 2015), was presented and discussed, and subsequently endorsed by the Panel on 11 June.

The technical report will be published together with the Opinion related to the dietary reference values for vitamin E as α -tocopherol (see also item 5.9) in the coming weeks.

5.9. Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Dietary Reference Values for vitamin E as α -tocopherol (EFSA-Q-2011-01231)

On 11 June, a draft opinion, which takes into consideration relevant comments received from the public consultation (see item 5.8), was

⁵ The next meeting of the NDA Panel will be held on 29 June – 1 July 2015.

⁶ The claimed effect considered by the Panel is: "lowering of blood pressure is a beneficial physiological effect for people who want to lower their blood pressure. Increased blood pressure is a risk factor for hypertension" (see the published opinion).

introduced and discussed. This document proposes dietary reference values for vitamin E as α -tocopherol for adults, infants and children, and pregnant and lactating women. The draft opinion was adopted by the Panel on 11 June subject to the incorporation of editorial changes.

The full text will be published in the coming weeks via this link:
<http://www.efsa.europa.eu/en/efsajournal/pub/4149.htm>

5.10. Draft technical report on the outcome of the public consultation on the Draft Scientific Opinion on the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on Dietary Reference Values for cobalamin (vitamin B12) (EFSA-Q-2015-00100)

A technical report on the Outcome of a public consultation on a draft Opinion related to the dietary reference values for cobalamin, which summarises the comments received during the public consultation on this opinion (which was open from 10 March to 21 April 2015), was presented and discussed, and subsequently endorsed by the Panel on 11 June.

The technical report will be published together with the Opinion related to the dietary reference values for cobalamin (see also item 5.11) in the coming weeks.

5.11. Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Dietary Reference Values for cobalamin (vitamin B12) (EFSA-Q-2011-01227)

On 11 June, a draft opinion, which takes into consideration relevant comments received from the public consultation (see item 5.10), was introduced and discussed. This document proposes dietary reference values for cobalamin for adults, infants and children, and pregnant and lactating women. The draft opinion was adopted by the Panel on 11 June subject to the incorporation of editorial changes.

The full text will be published in the coming weeks via this link:
<http://www.efsa.europa.eu/en/efsajournal/pub/4150.htm>

5.12. Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the Dietary Reference Values for copper (EFSA-Q-2011-01210)

On 11 June, the draft opinion was introduced and discussed. This document proposes dietary reference values for copper for adults, infants and children, and pregnant and lactating women. It was endorsed by the Panel on 12 June for release for public consultation, subject to incorporation of editorial comments.

The full text will be released for public consultation in the coming weeks.
<http://www.efsa.europa.eu/en/consultations/call/150629a.htm>

6. New Mandates

6.1. Applications pursuant to Article 14/13.5 of Regulation (EC) No 1924/2006

As of 8 June 2015, eight health claims applications are in progress.

Since the last Plenary meeting:

- Six article 14 claims were received:
 - 0050_FR - Hydrolysed cereals and easy digestion (EFSA-Q-2008-130).
 - 0061_FR - Non digestible oligosaccharide fibres (FOS/inulin, GOS and a mixture of FOS/inulin and GOS) are prebiotics that promote a healthy gut as clinically shown by an improvement of intestinal transit, an increase in beneficial bacteria and a decrease in potentially pathogenic bacteria in the gut (EFSA-Q-2008-141).
 - 0102_FR - Vitamin D contributes to the normal function of natural defences (EFSA-Q-2008-182).
 - 0105_FR - Vitamin B3 (niacin) needed to release energy from foods (EFSA-Q-2008-185).
 - 0108_FR - Vitamin B7 (biotin) and metabolism of food to release energy (EFSA-Q-2008-188).
 - 0123_FR - Starch and thicken the product to limit spitting-up (EFSA-Q-2008-204).
- Two Article 13.5 applications (claims based on newly developed science and/or which include a request for the protection of proprietary data) were received: "A characteristic collagen peptide mixture (FORTIGEL) that contributes to the maintenance of normal joint function" (EFSA-Q-2015-00360); "Lactitol and maintenance of normal bowel function" (EFSA-Q-2015-00375). One Article 13.5 application was withdrawn: "the combined ingestion of glucose and fructose improves performance in active individuals performing endurance exercise" (EFSA-Q-2014-00927).

6.2. Other mandates

A new request was received from the European Commission in the context of Regulation (EC) No 258/97:

EFSA is asked to carry out additional assessment on fermented soybean extract (Nattokinase-NSK-SD®) as a novel food ingredient (EFSA-Q-2015-00294).

7. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission

7.1. Scientific Committee and other Scientific Panels

Members were briefed about the on-going activities of the Scientific Committee (SC) and its working groups:

The Draft guidance on uncertainty in risk assessment was endorsed by the Scientific Committee (SC) for public consultation. A one-year trial period including training will be put in place to apply the guidance.

The potential thematic areas for the next thematic grants of common interest in the EU are being consulted with the Advisory Forum and Scientific Committee for further suggestions to take into account possible interests and needs in 2016. Panels were also invited to propose Thematic Grants Areas for 2016 by 7 August 2015.

Members were also briefed about the on-going activities of the SC's working group on Biological Relevance.

7.2. EFSA including its Working Groups/Task Forces

The Panel was informed that EFSA has published the list of experts who are joining EFSA Scientific Panels and Scientific Committee, starting their three-year term as of 1st July 2015, together with their CVs and declarations of interest (<http://www.efsa.europa.eu/en/press/news/150608.htm>).

The inaugural meeting of the NDA Panel's three-year mandate will take place on 1 July at EFSA's premises in Parma. During these meetings, experts will be informed about EFSA strategy, risk assessment, and the Authority's policy on independence and implementing rules. Each Panel will also meet separately to discuss its future work programmes and elect its Chair and vice-Chairs.

Chairs of Working Groups (WG) also reported back regarding their respective latest meetings (see respective published minutes).

7.3. European Commission

The Commission representative provided an update on the status of its decision making process related to EFSA-adopted scientific opinions.

8. Other scientific topics for information and/or discussion

8.1. Draft technical report on outcome of the public consultation on the draft guidance on the scientific requirements for health claims related to the gastro-intestinal tract, the immune system, and defence against pathogenic microorganisms (EFSA-Q-2015-00017)

On 12 June, the Nutrition Unit presented the draft technical report which summarised the comments received during the public consultation and reported how the comments were addressed. A revised draft will be presented to the next NDA plenary meeting⁵ for further discussion and possible endorsement.

8.2. Draft guidance on the scientific requirements for health claims related to the gastro-intestinal tract, the immune system, and defence against pathogenic microorganisms (EFSA-Q-2014-00353)

On 12 June, the Nutrition Unit presented a draft guidance, taking into account the comments received during the public consultation. A revised draft will be presented to the next NDA plenary meeting⁵ for further discussion and possible adoption.

9. Any other business

The next plenary meeting of the NDA Panel is scheduled to take place on 29 June – 01 July 2015 in Parma.